EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostication with Thyroid GuidePx in the context of tall cell variants

Steven Craig, Cynthia Stretch, Caitlin Yeo, Jeremy Fan, Haley Pedersen, Young Joo Park, Adrian Harvey, Oliver F Bathe

Surgery · 2025

DOI: 10.1016/j.surg.2024.06.080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Surgery, 2025. Verfasst von Steven Craig und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Illawarra Shoalhaven Local Health District, Warrawong, New South Wales, Australia; Graduate School of Medicine, University of …. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyroid Cancer, Papillary, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alberta Innovates, Alberta Health Services, Illawarra Shoalhaven Local Health District.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The tall cell variant of papillary thyroid cancer generally has a worse prognosis compared with the classical variant. Thyroid GuidePx is a genomic classifier capable of classifying papillary thyroid cancer into 3 molecular subtypes using fine-needle aspirate. Type 1 and 2 have low recurrence rates, particularly in early tumors (1-4 cm and N0). Type 3 is characterized by aggressive biology and high recurrence rates regardless of size and lymph node status. The study examines the interaction of tall cell variant histology with Thyroid GuidePx risk stratification. METHODS: Gene expression data from 736 patients (The Cancer Genome Atlas, Canada, and South Korea), were submitted to the Thyroid GuidePx classifier. Results across the 3 molecular subtypes were further dichotomized into "early" papillary thyroid cancer (tumor size 1-4 cm and N0) (n = 369; 51%) or "advanced" papillary thyroid cancer (n = 359; 49%). Structural recurrence was the primary outcome measure in our analysis. Transcriptomic and genomic analysis was conducted to explore what biological differences could account for clinical differences between tall cell variant and non- tall cell variants. RESULTS: Thyroid GuidePx identified 369 early papillary thyroid cancers: 129 (35%) type 1, 168 (45.5%) type 2, and 72 (19.5%) type 3. The recurrence rates for early type 1, type 2, and type 3 papillary thyroid cancers were 3.9%, 1.9%, and 19.4%, respectively. There were no type 1 tall cell variants. In type 2 papillary thyroid cancers, the incidence of tall cell variant was greater in advanced than early papillary thyroid cancers (10.2% vs 4.2%, P = .04). Notably, none of the 7 early type 2 tall cell variants recurred. In type 3 papillary thyroid cancers, the prevalence of tall cell variants was similar in early and advanced tumors (10% vs 9%, NS). When compared with non-tall cell variants, early type 3 tall cell variants trended toward greater recurrence (28.6% vs 18.5%, not significant) whereas advanced type 3 tall cell variants had a significantly greater recurrence rate (50% vs 28.6%, P = .01). Biologically, type 3 tall cell variants had had a pronounced enrichment in cell proliferation, epithelial-mesenchymal transition, invasion, and inflammation. CONCLUSION: Thyroid GuidePx reliably identifies a low-risk subgroup (early type 1 and early type 2 papillary thyroid cancers) for which conservative procedures would be appropriate. Tall cell variants in this subgroup are uncommon (1.2%), and none of the tall cell variants in this subgroup recurred. Type 3 papillary thyroid cancers have greater recurrence rates in both early and advanced papillary thyroid cancers. Tall cell variant appears to further increase recurrence in this subgroup.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsThyroid Cancer, PapillaryNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedPrognosisAdultBiopsy, Fine-NeedleAgedGene Expression ProfilingRepublic of KoreaRisk AssessmentThyroidectomyThyroid Gland

Autor:innen und Institutionen

  • Department of Surgery, Illawarra Shoalhaven Local Health District, Warrawong, New South Wales, Australia; Graduate School of Medicine, University of Wollongong, Warrawong, New South Wales, Australia.
  • Department of Oncology, Cumming School of Medicine, University of Calgary, AB, Canada; Qualisure Diagnostics Inc, Calgary, AB, Canada. Electronic address: https://twitter.com/CynStre.
  • Department of Surgery, Cumming School of Medicine, University of Calgary, AB, Canada.
  • Qualisure Diagnostics Inc, Calgary, AB, Canada.
  • Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Republic of Korea; Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of…
  • Department of Oncology, Cumming School of Medicine, University of Calgary, AB, Canada; Qualisure Diagnostics Inc, Calgary, AB, Canada; Department of Surgery, Cumming School of Medicine, University of Calgary, AB, Canada…

Förderung

  • Alberta Innovates
  • Alberta Health Services
  • Illawarra Shoalhaven Local Health District

Zitieren

APA

Craig, S., Stretch, C., Yeo, C., Fan, J., Pedersen, H., Park, Y. J., Harvey, A., & Bathe, O. F. (2025). Prognostication with Thyroid GuidePx in the context of tall cell variants. Surgery. https://doi.org/10.1016/j.surg.2024.06.080

Vancouver

Craig S, Stretch C, Yeo C, Fan J, Pedersen H, Park YJ, et al. Prognostication with Thyroid GuidePx in the context of tall cell variants. Surgery. 2025. doi:10.1016/j.surg.2024.06.080

BibTeX
@article{Craig2025,
  author = {Craig, Steven and Stretch, Cynthia and Yeo, Caitlin and Fan, Jeremy and Pedersen, Haley and Park, Young Joo and Harvey, Adrian and Bathe, Oliver F},
  title = {Prognostication with Thyroid GuidePx in the context of tall cell variants},
  journal = {Surgery},
  year = {2025},
  doi = {10.1016/j.surg.2024.06.080}
}
Kostenlos starten →